<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615467</url>
  </required_header>
  <id_info>
    <org_study_id>18629</org_study_id>
    <secondary_id>J2P-MC-LXBE</secondary_id>
    <nct_id>NCT05615467</nct_id>
  </id_info>
  <brief_title>A Study of Effect of LY3556050 on Metformin in Healthy Participants</brief_title>
  <official_title>An Open-Label Study in Healthy Participants to Evaluate the Effect of LY3556050 on Metformin Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate how much Metformin gets into the bloodstream&#xD;
      and how long the body takes to get rid of it when it is administered orally in combination&#xD;
      with LY3556050 in healthy participants. Iohexol will be administered to evaluate kidney&#xD;
      function. Each enrolled participant will remain in the study for up to 7 weeks including the&#xD;
      screening period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2022</start_date>
  <completion_date type="Actual">December 27, 2022</completion_date>
  <primary_completion_date type="Actual">December 27, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Metformin</measure>
    <time_frame>Predose on day 1 through 13 days postdose</time_frame>
    <description>PK: AUC of Metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of Metformin</measure>
    <time_frame>Predose on day 1 through 13 days postdose</time_frame>
    <description>PK: Cmax of Metformin</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3556050 + Metformin + Iohexol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3556050 administered orally in combination with metformin given orally and iohexol given intravenously (IV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3556050</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3556050 + Metformin + Iohexol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3556050 + Metformin + Iohexol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>LY3556050 + Metformin + Iohexol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants who are overtly healthy as determined by medical&#xD;
             evaluation&#xD;
&#xD;
          -  Participants with body weight of at least 50 kilograms (kg) or more and have a body&#xD;
             mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg/mÂ²)&#xD;
&#xD;
          -  Have an ECG at screening considered to be within acceptable limits by the investigator&#xD;
&#xD;
          -  Male participants who agree to use contraception and female participants of child&#xD;
             bearing potential who agree to use contraception and women not of child bearing&#xD;
             potential may participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are lactating&#xD;
&#xD;
          -  Have known allergies or contraindications to LY3556050, metformin, iodine, iohexol, or&#xD;
             other contrast agents, related compounds or any components of their formulation, or&#xD;
             history of significant atopy&#xD;
&#xD;
          -  Have a history, or ECG findings, of clinically significant bradycardia, heart block,&#xD;
             tachycardia, sick sinus syndrome/sinoatrial block, first-degree AV block, or second-&#xD;
             or third-degree AV block, bundle branch block or other tachy- or brady-arrhythmias; o&#xD;
             rhave any other abnormality in the 12-lead ECG that, in the opinion of the&#xD;
             investigator, confounds assessment of QT interval or increases the risks associated&#xD;
             with participating in the study&#xD;
&#xD;
          -  Have active or a history of gastritis or peptic ulcer disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 11, 2022</study_first_submitted>
  <study_first_submitted_qc>November 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>January 17, 2023</last_update_submitted>
  <last_update_submitted_qc>January 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

